Beijing, Shanghai & Boston, Mar. 17, 2023 — Jacobio Pharma (1167.HK) has received IND (Investigational New Drug) approval of its self-developed drug GUE inhibitor JAB-24114 from the Center for Drug Evaluation (CDE) of China. Jacobio plans to initiate a Phase I/IIa clinical trial in the China.

Tumor growth is highly dependent on glutamine, which can be converted into various metabolites by multiple glutamine-utilizing enzymes (GUEs). These metabolites support a variety of tumor growth pathways such as TCA cycles, nucleotide synthesis, purine synthesis and amino acid synthesis. JAB-24114 can inhibit multiple GUEs, leading to simultaneous blockade of multiple glutamine metabolism pathways, with great therapeutic potential. Compared with its similar product, JAB-24114 has a wider therapeutic window. Preclinical in vivo study exhibited that JAB-24114 can effectively inhibit tumor growth in multiple animal models. 

JAB-24114 has the distinctive combination effects of depleting tumors of nutrients while enhancing T cell function. Synergistic action with anti-PD-(L)1 can boost the anti-tumor effect. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors. Jacobio has self-developed SHP2 inhibitors (JAB-3312 and JAB-3068), KRAS G12C inhibitor Glecirasib (JAB-21822), and KRASmulti inhibitor (JAB-23400), which have potential to provide more combination therapies to patients. 

Jacobio is committed to developing global first-in-class drugs, and key programs are targeting among the top three worldwide. Currently there is only one program in the Phase I clinical stage in respective drug class globally.
 

About Jacobio